Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.addr.2017.05.011 http://scihub22266oqcxt.onion/10.1016/j.addr.2017.05.011 C5647831!5647831!28545888     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28545888.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Adv+Drug+Deliv+Rev 2017 ; 114 (ä): 79-101 Nephropedia Template TP {{tp|p=28545888|t=2017. Delivering safer immunotherapies for cancer |pdf=|usr=}}{{28545888}} gab.com Text Delivering safer immunotherapies for cancer JO: Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=28545888 #FOAvip Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new drug approvals and a massive pipeline of additional treatments in clinical and preclinical development. However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-specific systemic inflammation and autoimmune side effects. Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities. Here we review mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss approaches based in drug delivery technology to enhance the safety and potency of these treatments. These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally. Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential. Twit Text FOAVip Delivering safer immunotherapies for cancer ????Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=28545888 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28545888 #FOAvip English Wikipedia <ref>{{Cite pmid|28545888}}</ref> Delivering safer immunotherapies for cancer #MMPMID28545888 Milling L; Zhang Y; Irvine DJ Adv Drug Deliv Rev 2017[May]; 114 (ä): 79-101 PMID28545888show ga Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new drug approvals and a massive pipeline of additional treatments in clinical and preclinical development. However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-specific systemic inflammation and autoimmune side effects. Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities. Here we review mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss approaches based in drug delivery technology to enhance the safety and potency of these treatments. These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally. Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential. äDelivering safer immunotherapies for cancer (epmc).pdf DeepDyve Pubget Overpricing